KIYATEC enrolls first patients with solid tumors in clinical study of its EV3D drug r
KIYATEC, Inc. today announced the enrollment of the first patients in a U.S. clinical study of its Ex Vivo 3D drug response assay across several difficult-to-treat solid tumors.
More... |
All times are GMT -7. The time now is 04:48 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021